Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jbe who wrote (804)	3/15/2000 3:47:00 AM
From: Luke	Read Replies (1) \| Respond to of 52153

Motley fool's right on, in contrast to stuff put out by other like (i think nbc or reuters). Investors did not read beyond the headline. In any case, the more info in the public, the more gene based products will reach market or development stage, and the more the value of the underlying gene patents! BUT, the reason it's a big plus IMO is that last fall, Clinton-Blair made headlines by saying gene patents should be banned. The timing of that statement was not right, and less people cared; in addition, the mechanism for banning those would seem extremely problematic. This time, C-B got much more political mileage out of their hype. But this time, they seem to reverse their stance 180 degrees on patents. A huge plus for all genomics.